VESTICAP CAPSULES 16MG

Composition

1 capsule contains: betahistine dihydrochloride 8, 16 or 24 mg

Pharmacotherapeutic group

Histamine drug

pharmachologic effect

Agonist of H1-histamine receptors of the inner ear vessels and antagonist of H3-histamine receptors of the vestibular nuclei of the central nervous system (CNS). By relaxing the precapillary sphincters of the vessels of the inner ear, it improves blood circulation in the vascular strip of the inner ear. Dozavisimo reduces the generation of action potentials in the neurons of the lateral and medial vestibular nuclei. Accelerates the recovery of vestibular function after unilateral vestibular neuroectomy, accelerating and facilitating central vestibular compensation (due to antagonism with histamine H3 receptors). Relieves symptoms in Meniere's syndrome and vestibular vertigo. A stable therapeutic effect occurs after 14 days.

Indications for use

Treatment of Meniere's syndrome, characterized by dizziness (accompanied by nausea and vomiting), hearing loss and tinnitus.

Symptomatic treatment of vestibular vertigo (vertigo).

Contraindications

Hypersensitivity, pregnancy and lactation, children's age.

Lactose intolerance, lactase deficiency and glucose-galactose malabsorption syndrome.

Dosage and administration

Inside, 8 mg for 1 -2 capsule 3 times a day, 16 mg - 1 capsule 3 times a day, 24 mg - 1 capsule 2 times a day. Dose and duration of admission are selected individually.

Release form

8 mg, 16 or 24 mg in 30 capsules in a blister pack

Pharmacy sales terms

On prescription.